Armenian Ministry of Health considers "Armenicum" an effective drug  and does its best to increase its production and raise international  recognition

ArmInfo. With the purpose of revealing the expediency of the activity of the "Armenicum" Clinical Center, increasing the effectiveness of patient treatment, and  stimulating the international recognition of the "Armenicum" drug, a working group was created with the participation of specialists from the Ministry of Health, leading physicians, representatives of the Ministry of Defense and the center itself.

As Minister of Health Levon Altunyan noted in his conversation with  ArmInfo correspondent, it is too early to speak about the results of  the working group's activity. "But if it turns out that due to the  money saved for the maintenance of the building and the  administrative staff of the Center, we will be able to increase  funding for the treatment of patients, preclinical and clinical  trials of the" Armenicum "drug, as well as to increase its  international recognition, we will go for it," explained Altunyan,  adding that in this case patients will undergo treatment in other  medical centers. At the same time, he stressed that if the effects  and expectations from optimization are small, everything will remain  as it is.

As for the approach of Ministry of health to "Armenicum", as an  effective drug, it, according to the minister, has not undergone any  changes. "We still consider this drug to be very effective in the  treatment of HIV/AIDS and many other diseases, moreover, we are now  doing everything possible to increase its consumption and keep  production. If we manage to raise additional funds from optimizing  the expenses for the maintenance of the center" Armenicum "they will  be directed to preclinical and clinical trials of the drug in order  to ensure its international recognition," the minister summed up. It  should be noted that the preparation "Armenicum" during clinical  trials has proved itself not only as a tool for the treatment of  HIV/AIDS, but also for hepatitis C, many system diseases, diabetes,  etc. Clinical trials of the drug have been conducted since the  beginning of the 2000s.